Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting

A Review of Selected Presentations From the ACG 2023 Annual Scientific Meeting • October 20-25, 2023 • Vancouver, Canada Early Symptomatic Improvement With Guselkumab Induction Treatment […]

Letter From the Editor: Small Molecule and Biologic Therapies for Ulcerative Colitis

Currently, there are a number of different small molecule and biologic therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients […]

Choosing Among Small Molecule and Biologic Therapies for Patients With Ulcerative Colitis

G&H How do the small molecule and biologic therapies currently approved for ulcerative colitis differ in terms of mechanism of action and mode of administration? DH […]

Highlights in Ulcerative Colitis From the 18th Congress of ECCO

A Review of Selected Presentations From the ECCO Meeting • March 1-4, 2023 • Copenhagen, Denmark Analyses From the Phase 3 True North Study of Ozanimod […]

Rescue Therapy for Acute Severe Ulcerative Colitis: A Case Report

Patient Presentation A 64-year-old man without a significant past medical history presented to a tertiary care center for a second opinion regarding management of his inflammatory […]

Highlights in Ulcerative Colitis From the American College of Gastroenterology Annual Scientific Meeting

A Review of Selected Presentations From ACG 2022 October 21-26, 2022 • Charlotte, North Carolina Duration of Response to Ozanimod After Treatment Withdrawal: Results From the […]

Shooting for the Stars: Review of the STARDUST Trial and the Treat-to-Target Approach for Crohn’s Disease

Abstract: Crohn’s disease (CD) and ulcerative colitis, collectively termed inflammatory bowel disease, are progressive autoimmune conditions of the gastrointestinal tract. Mucosal healing has been associated with […]

Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn’s and Colitis Organisation

Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North Ozanimod is […]

Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn’s Disease and Ulcerative Colitis

Abstract: Patients with Crohn’s disease (CD) or ulcerative colitis (UC) have high morbidity rates owing to debilitating intestinal complications and extraintestinal manifestations (EIMs). We retrospectively identified […]

Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature

Abstract: Using 2 or more treatment modalities to achieve a synergistic effect in patients with refractory inflammatory bowel disease (IBD) has been an area of focus […]

Review of the Landmark VARSITY Trial

G&H Why is the VARSITY trial still important and clinically relevant? BF The VARSITY trial was a landmark study that provided many insights into the treatment […]

Alcohol Use in Patients With Inflammatory Bowel Disease

Abstract: Alcohol consumption is common in patients with inflammatory bowel disease (IBD), but alcohol has been reported to be the most-avoided diet item by this patient […]

The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice

Introduction In October 2020 and January 2021, a group of clinical experts in the field of inflammatory bowel disease (IBD) convened virtually to discuss current ulcerative […]

Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic

Abstract: Inflammatory bowel disease and the subsequent immunosuppressive regimens used to treat this condition increase the risk for acquiring viral and bacterial infections. Ensuring that […]

Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease

Abstract: Hospitalization for inflammatory bowel disease is common and requires coordination of care. The goals of hospitalization are to markedly improve symptoms, transition management to […]

INFORM UC: An Update on Contemporary Management of UC

Introduction In July 2020, a group of clinical experts in the field of inflammatory bowel disease (IBD) convened virtually to discuss current issues and advances […]

Impact of Obesity on the Management of Inflammatory Bowel Disease

Abstract: The worldwide prevalence of obesity has reached staggering proportions, and the inflammatory bowel disease (IBD) population has not been immune to this trend, with […]

Mucosal Healing in Crohn’s Disease and Ulcerative Colitis

G&H How has the definition of mucosal healing evolved? LP-B For many decades, mucosal healing equaled endoscopic healing. The main change is that, for several years […]

Overlap Between Irritable Bowel Syndrome and Inflammatory Bowel Disease

G&H What features do irritable bowel syndrome and inflammatory bowel disease have in common? AF It is important to note that bowel symptoms are not […]

Clinical Implications of the Recent Dose-Ranging Studies of Adalimumab

G&H How was adalimumab dosing determined for the treatment of Crohn’s disease and ulcerative colitis? BF Currently, standard induction dosing is 160 mg initially, followed […]